These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

342 related articles for article (PubMed ID: 36307613)

  • 1. Interdisciplinary risk counseling for hereditary breast and ovarian cancer: real-world data from a specialized center.
    Zang B; Helms M; Besch L; Kalmbach N; Stegen S; Blohmer JU; Speiser D
    Arch Gynecol Obstet; 2023 May; 307(5):1585-1592. PubMed ID: 36307613
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Extended genetic analysis and tumor characteristics in over 4600 women with suspected hereditary breast and ovarian cancer.
    Öfverholm A; Törngren T; Rosén A; Arver B; Einbeigi Z; Haraldsson K; Ståhlbom AK; Kuchinskaya E; Lindblom A; Melin B; Paulsson-Karlsson Y; Stenmark-Askmalm M; Tham E; von Wachenfeldt A; Kvist A; Borg Å; Ehrencrona H
    BMC Cancer; 2023 Aug; 23(1):738. PubMed ID: 37563628
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Gene panel testing of 5589 BRCA1/2-negative index patients with breast cancer in a routine diagnostic setting: results of the German Consortium for Hereditary Breast and Ovarian Cancer.
    Hauke J; Horvath J; Groß E; Gehrig A; Honisch E; Hackmann K; Schmidt G; Arnold N; Faust U; Sutter C; Hentschel J; Wang-Gohrke S; Smogavec M; Weber BHF; Weber-Lassalle N; Weber-Lassalle K; Borde J; Ernst C; Altmüller J; Volk AE; Thiele H; Hübbel V; Nürnberg P; Keupp K; Versmold B; Pohl E; Kubisch C; Grill S; Paul V; Herold N; Lichey N; Rhiem K; Ditsch N; Ruckert C; Wappenschmidt B; Auber B; Rump A; Niederacher D; Haaf T; Ramser J; Dworniczak B; Engel C; Meindl A; Schmutzler RK; Hahnen E
    Cancer Med; 2018 Apr; 7(4):1349-1358. PubMed ID: 29522266
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Germline variants in DNA repair genes associated with hereditary breast and ovarian cancer syndrome: analysis of a 21 gene panel in the Brazilian population.
    da Costa E Silva Carvalho S; Cury NM; Brotto DB; de Araujo LF; Rosa RCA; Texeira LA; Plaça JR; Marques AA; Peronni KC; Ruy PC; Molfetta GA; Moriguti JC; Carraro DM; Palmero EI; Ashton-Prolla P; de Faria Ferraz VE; Silva WA
    BMC Med Genomics; 2020 Feb; 13(1):21. PubMed ID: 32039725
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Increasing referral of at-risk women for genetic counseling and BRCA testing using a screening tool in a community breast imaging center.
    Arun BK; Peterson SK; Sweeney LE; Bluebond RD; Tidwell RSS; Makhnoon S; Kushwaha AC
    Cancer; 2022 Jan; 128(1):94-102. PubMed ID: 34424535
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Screening for BRCA1, BRCA2, CHEK2, PALB2, BRIP1, RAD50, and CDH1 mutations in high-risk Finnish BRCA1/2-founder mutation-negative breast and/or ovarian cancer individuals.
    Kuusisto KM; Bebel A; Vihinen M; Schleutker J; Sallinen SL
    Breast Cancer Res; 2011 Feb; 13(1):R20. PubMed ID: 21356067
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Landscape of pathogenic variations in a panel of 34 genes and cancer risk estimation from 5131 HBOC families.
    Castéra L; Harter V; Muller E; Krieger S; Goardon N; Ricou A; Rousselin A; Paimparay G; Legros A; Bruet O; Quesnelle C; Domin F; San C; Brault B; Fouillet R; Abadie C; Béra O; Berthet P; ; Frébourg T; Vaur D
    Genet Med; 2018 Dec; 20(12):1677-1686. PubMed ID: 29988077
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Germline mutational variants of Turkish ovarian cancer patients suspected of Hereditary Breast and Ovarian Cancer (HBOC) by next-generation sequencing.
    Tuncer SB; Celik B; Erciyas SK; Erdogan OS; Gültaslar BK; Odemis DA; Avsar M; Sen F; Saip PM; Yazici H
    Pathol Res Pract; 2024 Feb; 254():155075. PubMed ID: 38219492
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [The French Genetic and Cancer Consortium guidelines for multigene panel analysis in hereditary breast and ovarian cancer predisposition].
    Moretta J; Berthet P; Bonadona V; Caron O; Cohen-Haguenauer O; Colas C; Corsini C; Cusin V; De Pauw A; Delnatte C; Dussart S; Jamain C; Longy M; Luporsi E; Maugard C; Nguyen TD; Pujol P; Vaur D; Andrieu N; Lasset C; Noguès C;
    Bull Cancer; 2018 Oct; 105(10):907-917. PubMed ID: 30268633
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Identification of germline pathogenic variants in DNA damage repair genes by a next-generation sequencing multigene panel in BRCAX patients.
    Rodríguez-Balada M; Roig B; Melé M; Albacar C; Serrano S; Salvat M; Querol M; Borràs J; Martorell L; Gumà J
    Clin Biochem; 2020 Feb; 76():17-23. PubMed ID: 31786208
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Hereditary breast and ovarian cancer: assessment of point mutations and copy number variations in Brazilian patients.
    Silva FC; Lisboa BC; Figueiredo MC; Torrezan GT; Santos EM; Krepischi AC; Rossi BM; Achatz MI; Carraro DM
    BMC Med Genet; 2014 May; 15():55. PubMed ID: 24884479
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Prevalence of germline variants in consensus moderate-to-high-risk predisposition genes to hereditary breast and ovarian cancer in BRCA1/2-negative Brazilian patients.
    Gomes R; Spinola PDS; Brant AC; Matta BP; Nascimento CM; de Aquino Paes SM; Bonvicino CR; Dos Santos ACE; Moreira MAM
    Breast Cancer Res Treat; 2021 Feb; 185(3):851-861. PubMed ID: 33128190
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Multigene panel testing beyond BRCA1/2 in breast/ovarian cancer Spanish families and clinical actionability of findings.
    Bonache S; Esteban I; Moles-Fernández A; Tenés A; Duran-Lozano L; Montalban G; Bach V; Carrasco E; Gadea N; López-Fernández A; Torres-Esquius S; Mancuso F; Caratú G; Vivancos A; Tuset N; Balmaña J; Gutiérrez-Enríquez S; Diez O
    J Cancer Res Clin Oncol; 2018 Dec; 144(12):2495-2513. PubMed ID: 30306255
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Mutation screening of TP53, CHEK2 and BRCA genes in patients at high risk for hereditary breast and ovarian cancer (HBOC) in Brazil.
    Cipriano NM; de Brito AM; de Oliveira ES; de Faria FC; Lemos S; Rodrigues AN; de Oliveira Lopes D; Dos Santos LL
    Breast Cancer; 2019 May; 26(3):397-405. PubMed ID: 30535581
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The identification of pathogenic variants in BRCA1/2 negative, high risk, hereditary breast and/or ovarian cancer patients: High frequency of FANCM pathogenic variants.
    Schubert S; van Luttikhuizen JL; Auber B; Schmidt G; Hofmann W; Penkert J; Davenport CF; Hille-Betz U; Wendeburg L; Bublitz J; Tauscher M; Hackmann K; Schröck E; Scholz C; Wallaschek H; Schlegelberger B; Illig T; Steinemann D
    Int J Cancer; 2019 Jun; 144(11):2683-2694. PubMed ID: 30426508
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Recommendations for Preventive Care for Women with Rare Genetic Cause of Breast and Ovarian Cancer.
    Foretová L; Navrátilová M; Svoboda M; Vašíčková P; Sťahlová EH; Házová J; Kleiblová P; Kleibl Z; Macháčková E; Palácová M; Petráková K
    Klin Onkol; 2019; 32(Supplementum2):6-13. PubMed ID: 31409076
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Clinical utility of hereditary cancer panel testing: Impact of PALB2, ATM, CHEK2, NBN, BRIP1, RAD51C, and RAD51D results on patient management and adherence to provider recommendations.
    Vysotskaia V; Kaseniit KE; Bucheit L; Ready K; Price K; Johansen Taber K
    Cancer; 2020 Feb; 126(3):549-558. PubMed ID: 31682005
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Gene Sequencing for Pathogenic Variants Among Adults With Breast and Ovarian Cancer in the Caribbean.
    George SHL; Donenberg T; Alexis C; DeGennaro V; Dyer H; Yin S; Ali J; Butler R; Chin SN; Curling D; Lowe D; Lunn J; Turnquest T; Wharfe G; Cerbon D; Barreto-Coelho P; Schlumbrecht MP; Akbari MR; Narod SA; Hurley JE
    JAMA Netw Open; 2021 Mar; 4(3):e210307. PubMed ID: 33646313
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Comparison of hereditary breast and ovarian cancer syndrome and sporadic ovarian cancer in ovarian cancer BRCA mutations].
    Duan RR; Sun LX; Zhao HW
    Zhonghua Fu Chan Ke Za Zhi; 2021 Nov; 56(11):788-795. PubMed ID: 34823292
    [No Abstract]   [Full Text] [Related]  

  • 20. BRCA1 and BRCA2 Germline Mutation Analysis in Hereditary Breast/Ovarian Cancer Families from the Aures Region (Eastern Algeria): First Report.
    Mehemmai C; Cherbal F; Hamdi Y; Guedioura A; Benbrahim W; Bakour R; Abdelhak S
    Pathol Oncol Res; 2020 Apr; 26(2):715-726. PubMed ID: 30715675
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 18.